The pursuit of outperformance leads many investors to carefully choose individual stocks. Picking the right ones can be a game-changer for growing your wealth.
Caris Life Sciences Inc (NASDAQ: CAI) closed the day trading at $26.54 down -2.07% from the previous closing price of $27.1. In other words, the price has decreased by -$2.07 from its previous closing price. On the day, 2.02 million shares were traded. CAI stock price reached its highest trading level at $27.32 during the session, while it also had its lowest trading level at $26.11.
Ratios:
For a better understanding of CAI, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 9.36 and its Current Ratio is at 9.93. In the meantime, Its Debt-to-Equity ratio is 0.89 whereas as Long-Term Debt/Eq ratio is at 0.88.
Upgrades & Downgrades
In the most recent recommendation for this company, Canaccord Genuity on December 02, 2025, initiated with a Hold rating and assigned the stock a target price of $28. On July 14, 2025, Wolfe Research started tracking the stock assigning a Outperform rating and target price of $32. On July 14, 2025, TD Cowen started tracking the stock assigning a Buy rating and target price of $32.TD Cowen initiated its Buy rating on July 14, 2025, with a $32 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Dec 11 ’25 when LUKE POWER bought 62,250 shares for $27.10 per share.
Denton John Russel bought 4,184 shares of CAI for $100,793 on Nov 07 ’25. The insider now owns 9,184 shares after completing the transaction at $24.09 per share. On Nov 07 ’25, another insider, Spetzler David Baxley, who serves as the President of the company, bought 400 shares for $23.85 each. As a result, the insider paid 9,540 and bolstered with 460,777 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CAI now has a Market Capitalization of 7488179200 and an Enterprise Value of 7159424512. For the stock, the TTM Price-to-Sale (P/S) ratio is 11.54 while its Price-to-Book (P/B) ratio in mrq is 15.65. Its current Enterprise Value per Revenue stands at 11.03 whereas that against EBITDA is -135.201.
Stock Price History:
Over the past 52 weeks, CAI has reached a high of $42.50, while it has fallen to a 52-week low of $22.86. The 50-Day Moving Average of the stock is -6.08%, while the 200-Day Moving Average is calculated to be -11.77%.
Shares Statistics:
Over the past 3-months, CAI traded about 1.41M shares per day on average, while over the past 10 days, CAI traded about 3361150 shares per day. A total of 282.10M shares are outstanding, with a floating share count of 115.32M. Insiders hold about 59.13% of the company’s shares, while institutions hold 37.37% stake in the company. Shares short for CAI as of 1764288000 were 6840155 with a Short Ratio of 4.86, compared to 1761868800 on 4190099. Therefore, it implies a Short% of Shares Outstanding of 6840155 and a Short% of Float of 4.7.
Earnings Estimates
The stock of Caris Life Sciences Inc (CAI) is currently in the spotlight, with 3 analysts actively rating and assessing its market standing.The consensus estimate for the next quarter is -$0.05, with high estimates of -$0.04 and low estimates of -$0.06.
Analysts are recommending an EPS of between -$0.66 and -$0.73 for the fiscal current year, implying an average EPS of -$0.69. EPS for the following year is $0.2, with 5.0 analysts recommending between $0.46 and -$0.05.
Revenue Estimates
For the next quarter, 8 analysts are estimating revenue of $204.64M. There is a high estimate of $214M for the next quarter, whereas the lowest estimate is $200.7M.
Based on 9 analysts’ estimates, the company’s revenue will be $976.03M in the next fiscal year. The high estimate is $1.02B and the low estimate is $932.2M.
